Molecular mechanism and function of CD40/CD40L engagement in the immune system
By R. Elgueta, M. Benson, V. D. de Vries, A. Wasiuk, Yanxia Guo, R. Noelle. Immunological Reviews, 2009
1,529 citations recorded by the source corpus.
Summary: During the generation of a successful adaptive immune response, multiple molecular signals are required. A primary signal is the binding of cognate antigen to an antigen receptor expressed by T and B lymphocytes. Multiple secondary signals involve the engagement of costimulatory molecules expressed by T and B lymphocytes with their respective ligands. Because of its essential role in immunity, one of the best characterized of the costimulatory molecules is the receptor CD40. This receptor, a member of the tumor necrosis factor receptor family, is expressed by B cells, professional antigen‐presenting cells, as well as non‐immune cells and tumors. CD40 binds its ligand CD40L, which is transiently expressed on T cells and other non‐immune cells under inflammatory conditions. A wide spectrum of molecular and cellular processes is regulated by CD40 engagement including the initiation and progression of cellular and humoral adaptive immunity. In this review, we describe the downstream signaling pathways initiated by CD40 and overview how CD40 engagement or antagonism modulates humoral and cellular immunity. Lastly, we discuss the role of CD40 as a target in harnessing anti‐tumor immunity. This review underscores the essential role CD40 plays in adaptive immunity.
Subfields: Immunology
View Paper: https://www.semanticscholar.org/paper/5102832839146bc8145f5f06f81d689596e80f59
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Platelets at the interface of thrombosis, inflammation, and cancer. (2015, background): “CD154, also known as CD40 ligand, is a potent secretory molecule that elicits lymphocyte activation, and it has been the feature of numerous studies implicating its relevance for potentiating the adaptive immune response.(20) Platelets are the primary source of soluble CD154 released after agonist-d”
- 30 years of NF-κB: a blossoming of relevance to human pathobiology (2017, positive): “Moreover, CD40L activates the MAPK pathway in a NEMO-and ubiquitination-dependent fashion, revealing NF-κBindependent functions for NEMO (Elgueta et al., 2009).”
- Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “Many tumours have been shown to express CD40, including carcinomas of the ovary, nasopharynx, bladder, cervix, breast and prostate, and the engagement of CD40 can lead to a direct antitumour effect in some tumours in vivo”